Vical To Present TransVax(TM) CMV Vaccine Phase 2 Results at ICAAC and Host Concurrent Conference Call and Webcast
SAN DIEGO, Sept. 9, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced plans to present final results from the company's Phase 2 trial evaluating the potential for its TransVax™ therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed hematopoietic cell transplant (HCT) recipients. The company's abstract was accepted for a late-breaker session at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, Boston – September 12-15).
The company will release summary results from the trial before the opening of trading on Tuesday, September 14, and conduct an audio-only conference call and audio/slide webcast at 11:15 a.m. Eastern Time on Tuesday, September 14, concurrent with the session at ICAAC, to discuss additional details of the results with invited analysts and institutional investors. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, will join Vical management on the call. The call is open on a listen-only basis to any interested parties. The webcast audio and slides also will be available live and archived through the Events page of the company's website at www.vical.com.
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (888) 205-6648 begin_of_the_skype_highlighting (888) 205-6648 end_of_the_skype_highlighting, or (913) 981-5543 begin_of_the_skype_highlighting (913) 981-5543 end_of_the_skype_highlighting for international participants, and reference confirmation code 4384312. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112 begin_of_the_skype_highlighting (888) 203-1112 end_of_the_skype_highlighting, or (719) 457-0820 begin_of_the_skype_highlighting (719) 457-0820 end_of_the_skype_highlighting for international participants, and enter replay passcode 4384312. The call also will be available live and archived through the Events page at www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 begin_of_the_skype_highlighting (858) 646-1127 end_of_the_skype_highlighting or by e-mail at info@vical.com. |
